Lee Nuri, Jeong Seri, Lee Su Kyung, Cho Eun-Jung, Hyun Jungwon, Park Min-Jeong, Song Wonkeun, Kim Hyun Soo
Department of Laboratory Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, 1, Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea.
Department of Laboratory Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong-si 18450, Gyeonggi-do, Korea.
Vaccines (Basel). 2022 Jul 18;10(7):1143. doi: 10.3390/vaccines10071143.
We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 infection during the 4-month study period, with infection occurring 7−62 days before the second blood draw. Total antibody titers against the anti-spike (anti-S) and anti-nucleocapsid (anti-N) proteins of SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S and Elecsys Anti-SARS-CoV-2 assays (Roche), respectively. The median anti-S antibody titer in the non-infected groups at 4 months after the third dose was significantly decreased compared to that at 1 month after the third dose (from 17,777 to 3673 U/mL, p < 0.001). The infected group showed higher median anti-S antibody titers at 4 months (19,539 U/mL) than the non-infected group (3673 U/mL). The median anti-N antibody titer in the infected group at 4 months after the third dose was a 5.07 cut-off index (79.3% positivity). Anti-N antibody titers in the infected group were correlated with the number of days after SARS-CoV-2 infection. These data provide useful information for determining quarantine strategies and fourth vaccination requirements.
我们对两剂ChAdOx1 nCoV-19疫苗和第三剂BNT162b2加强针接种后的患者体内SARS-CoV-2抗体水平进行了定量分析。在第三剂接种后1个月和4个月，我们从149名医护人员处获取了255份血清样本。在149名参与者中，58人（38.9%）在4个月的研究期间感染了新冠病毒，感染发生在第二次采血前7至62天。分别使用罗氏公司的Elecsys Anti-SARS-CoV-2 S和Elecsys Anti-SARS-CoV-2检测法测定针对SARS-CoV-2刺突蛋白（抗S）和核衣壳蛋白（抗N）的总抗体滴度。第三剂接种后4个月，未感染组的抗S抗体滴度中位数与第三剂接种后1个月相比显著下降（从17,777降至3673 U/mL，p < 0.001）。感染组在4个月时的抗S抗体滴度中位数（19,539 U/mL）高于未感染组（3673 U/mL）。第三剂接种后4个月，感染组的抗N抗体滴度中位数为5.07临界指数（阳性率79.3%）。感染组的抗N抗体滴度与SARS-CoV-2感染后的天数相关。这些数据为确定检疫策略和第四剂疫苗接种要求提供了有用信息。
